Lumacaftor (VX-809)

For research use only. Not for use in humans.

目录号：S1565 别名： VRT 826809

CAS No. 936727-05-8

Lumacaftor (VX-809, VRT 826809)通过促进突变型CFTR(F508del-CFTR)的成熟，从而纠正囊性纤维症中常见的CFTR突变，在fisher大鼠甲状腺细胞中EC50为0.1 μM。Phase 3。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 2775.91	现货
5mg	RMB 1412.12	现货
10mg	RMB 2626.25	现货
50mg	RMB 7923.73	现货
200mg	RMB 16298.1	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Lumacaftor (VX-809)发表文献164篇：

Nat Med, 2018, 24(11):1732-1742

PubMed: 30297908 ( click the link to review the publication )

Nat Biotechnol, 2015, 33(8):845-852

PubMed: 26167629 ( click the link to review the publication )

Nat Med, 2013, 19(7):939-45

PubMed: 23727931 ( click the link to review the publication )

Nat Chem Biol, 2013, 9(7):444-54

PubMed: 23666117 ( click the link to review the publication )

Eur J Med Chem, 2021, 213:113186

PubMed: 33472120 ( click the link to review the publication )

Biomolecules, 2021, 11(3)422

PubMed: 33805605 ( click the link to review the publication )

J Biol Chem, 2021, S0021-9258(21)00378-1

PubMed: 33781744 ( click the link to review the publication )

Life (Basel), 2021, 11(2)131

PubMed: 33567498 ( click the link to review the publication )

Biomedicines, 2021, 9(2)117

PubMed: 33530577 ( click the link to review the publication )

J Cyst Fibros, 2021, S1569-1993(21)00028-X

PubMed: 33558100 ( click the link to review the publication )

Eur Respir J, 2020, 2002774

PubMed: 33303536 ( click the link to review the publication )

Sci Adv, 2020, 6(8):eaax9914

PubMed: 32128399 ( click the link to review the publication )

Cell Mol Life Sci, 2020, 10.1007/s00018-020-03448-4

PubMed: 31974654 ( click the link to review the publication )

Cells, 2020, 19;9(3)

PubMed: 32204475 ( click the link to review the publication )

PLoS Genet, 2020, 16(10):e1009100

PubMed: 33085659 ( click the link to review the publication )

Mol Ther Methods Clin Dev, 2020, 18;17:858-870

PubMed: 32373648 ( click the link to review the publication )

Mol Ther Methods Clin Dev, 2020, 12;17:1118-1128

PubMed: 32490033 ( click the link to review the publication )

Eur J Med Chem, 2020, 190:112116

PubMed: 32078860 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(12):E4524

PubMed: 32630527 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(12):E4486

PubMed: 32599772 ( click the link to review the publication )

Sci Rep, 2020, 21;10(1):8440

PubMed: 32439937 ( click the link to review the publication )

Sci Rep, 2020, 10(1):10935

PubMed: 32616918 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2020, 10.1152/ajplung.00137.2020

PubMed: 33296276 ( click the link to review the publication )

J Cyst Fibros, 2020, 10.1016/j.jcf.2020.01.011

PubMed: 32044246 ( click the link to review the publication )
J Cyst Fibros, 2020, S1569-1993(20)30123-5

PubMed: 32536510 ( click the link to review the publication )

PLoS One, 2020, 29;15(5):e0233439

PubMed: 32469934 ( click the link to review the publication )

JCI Insight, 2020, 138722

PubMed: 32673287 ( click the link to review the publication )

J Allergy Clin Immunol, 2020, S0091-6749(20)30811-3

PubMed: 32526307 ( click the link to review the publication )

FASEB Bioadv, 2020, 2(9):526-537

PubMed: 32923987 ( click the link to review the publication )

Am J Respir Crit Care Med, 2020, 10.1164/rccm.202004-1200LE

PubMed: 32687398 ( click the link to review the publication )

JCI Insight, 2020, 5(18)139983

PubMed: 32853178 ( click the link to review the publication )

Eur Respir J, 2020, 2000261

PubMed: 33184117 ( click the link to review the publication )

J Pers Med, 2020, 10(4)E209

PubMed: 33167369 ( click the link to review the publication )

Am J Respir Crit Care Med, 2019, 199(1):123-126

PubMed: 30326728 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1763

PubMed: 30992452 ( click the link to review the publication )

J Clin Invest, 2019, 129(8):3448-3463

PubMed: 31145101 ( click the link to review the publication )

J Clin Invest, 2019, 129(12):5236-5253

PubMed: 31657788 ( click the link to review the publication )

EMBO J, 2019, 38(4)

PubMed: 30643021 ( click the link to review the publication )

Cell Rep, 2019, 26(7):1701-1708

PubMed: 30759382 ( click the link to review the publication )

J Control Release, 2019, 296:225-231

PubMed: 30677435 ( click the link to review the publication )

Br J Pharmacol, 2019, 176(11):1764-1779

PubMed: 30825185 ( click the link to review the publication )

Sci Signal, 2019, 12(562)

PubMed: 30600261 ( click the link to review the publication )

Cell Physiol Biochem, 2019, 53(2):400-412

PubMed: 31403270 ( click the link to review the publication )

Hum Mutat, 2019, 40(10):1676-1683

PubMed: 31299140 ( click the link to review the publication )

Biochim Biophys Acta Mol Basis Dis, 2019, 1865(6):1323-1331

PubMed: 30716472 ( click the link to review the publication )

Biochim Biophys Acta Mol Basis Dis, 2019, 10.1016/j.bbadis.2019.165611

PubMed: 31740403 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(21)

PubMed: 31683989 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(19)

PubMed: 31590401 ( click the link to review the publication )
Sci Rep, 2019, 9(1):10310

PubMed: 31311979 ( click the link to review the publication )

Sci Rep, 2019, 9(1):17640

PubMed: 31776420 ( click the link to review the publication )

Sci Rep, 2019, 9(1):13729

PubMed: 31551433 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2019, 317(5):L690-L701

PubMed: 31508974 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2019, 317(1):L71-L86

PubMed: 30969810 ( click the link to review the publication )

Mol Pharmacol, 2019, 96(4):515-525

PubMed: 31427400 ( click the link to review the publication )

J Cyst Fibros, 2019, 10.1016/j.jcf.2019.01.012

PubMed: 30738802 ( click the link to review the publication )

J Cyst Fibros, 2019, 18(5):622-629

PubMed: 30366849 ( click the link to review the publication )

J Cyst Fibros, 2019, 10.1016/j.jcf.2019.08.021

PubMed: 31474496 ( click the link to review the publication )

Respir Res, 2019, 20(1):290

PubMed: 31864360 ( click the link to review the publication )

Cell Biosci, 2019, 9:69

PubMed: 31467667 ( click the link to review the publication )

Bioorg Med Chem, 2019, 27(1):79-91

PubMed: 30528127 ( click the link to review the publication )

PLoS One, 2019, 14(8):e0220984

PubMed: 31408507 ( click the link to review the publication )

PLoS One, 2019, 14(1):e0211290

PubMed: 30682135 ( click the link to review the publication )

Life Sci Alliance, 2019, 2(1)

PubMed: 30659068 ( click the link to review the publication )

FASEB Bioadv, 2019, 1(10):661-670

PubMed: 32123813 ( click the link to review the publication )

Br J Pharmacol, 2018, 175(20):3990-4002

PubMed: 30107029 ( click the link to review the publication )

Br J Pharmacol, 2018, 175(7):1017-1038

PubMed: 29318594 ( click the link to review the publication )

Cell Chem Biol, 2018, 25(7):891-905

PubMed: 29754957 ( click the link to review the publication )

Hum Mutat, 2018, 39(4):506-514

PubMed: 29271547 ( click the link to review the publication )

Hum Mol Genet, 2018, 27(6):969-984

PubMed: 29351619 ( click the link to review the publication )

Mol Pharm, 2018, 15(3):759-767

PubMed: 29384380 ( click the link to review the publication )

Sci Rep, 2018, 8(1):2759

PubMed: 29426890 ( click the link to review the publication )

Sci Rep, 2018, 8(1):13026

PubMed: 30158635 ( click the link to review the publication )
Am J Physiol Lung Cell Mol Physiol, 2018, 315(5):L846-L857

PubMed: 30136610 ( click the link to review the publication )

J Biol Chem, 2018, 293(29):11513-11526

PubMed: 29875161 ( click the link to review the publication )

Mol Pharmacol, 2018, 93(6):612-618

PubMed: 29618585 ( click the link to review the publication )

J Cyst Fibros, 2018, 17(5):595-606

PubMed: 29903467 ( click the link to review the publication )

J Cyst Fibros, 2018, 17(5):582-594

PubMed: 29936070 ( click the link to review the publication )

Front Pharmacol, 2018, 9:1490

PubMed: 30618775 ( click the link to review the publication )

Front Pharmacol, 2018, 9:719

PubMed: 30022950 ( click the link to review the publication )

Respir Res, 2018, 19(1):198

PubMed: 30290809 ( click the link to review the publication )

ChemMedChem, 2018, 13(14):1469-1478

PubMed: 29864241 ( click the link to review the publication )

J Bioenerg Biomembr, 2018, 50(2):117-129

PubMed: 29524019 ( click the link to review the publication )

SLAS Discov, 2018, 23(8):823-831

PubMed: 29533733 ( click the link to review the publication )

ERJ Open Res, 2018, 4(1)

PubMed: 29497617 ( click the link to review the publication )

JCI Insight, 2018, 3(4)

PubMed: 29467332 ( click the link to review the publication )

JCI Insight, 2018, 3(13)

PubMed: 29997283 ( click the link to review the publication )

JCI Insight, 2018, 3(14)

PubMed: 30046002 ( click the link to review the publication )

EMBO Mol Med, 2017, 9(9):1224-1243

PubMed: 28667089 ( click the link to review the publication )

Br J Pharmacol, 2017, 174(7):525-539

PubMed: 28094839 ( click the link to review the publication )

Hum Mol Genet, 2017, 26(16):3116-3129

PubMed: 28575328 ( click the link to review the publication )

Biochem Pharmacol, 2017, 136:24-31

PubMed: 28366727 ( click the link to review the publication )

J Biol Chem, 2017, 292(3):771-785

PubMed: 27895116 ( click the link to review the publication )

J Biol Chem, 2017, 292(9):3706-3719

PubMed: 28087700 ( click the link to review the publication )

Mol Pharmacol, 2017, 92(2):124-135

PubMed: 28546419 ( click the link to review the publication )

Front Pharmacol, 2017, 8:195

PubMed: 28439239 ( click the link to review the publication )

Front Cell Infect Microbiol, 2017, 7:470

PubMed: 29177135 ( click the link to review the publication )
SLAS Technol, 2017, 22(3):315-324

PubMed: 28376702 ( click the link to review the publication )

Mol Med Rep, 2017, 16(6):8849-8853

PubMed: 29039559 ( click the link to review the publication )

JCI Insight, 2017, 2(19)

PubMed: 28978796 ( click the link to review the publication )

JCI Insight, 2017, 2(22)

PubMed: 29202459 ( click the link to review the publication )

Sci Transl Med, 2016, 8(344):344ra84

PubMed: 27334259 ( click the link to review the publication )

Am J Respir Crit Care Med, 2016, 193(10):1123-33

PubMed: 26694899 ( click the link to review the publication )

J Hepatol, 2016, 64(6):1339-47

PubMed: 26879107 ( click the link to review the publication )

Eur Respir J, 2016, 48(2):451-8

PubMed: 27103391 ( click the link to review the publication )

Eur Respir J, 2016, 48(3):768-79

PubMed: 27471203 ( click the link to review the publication )

Br J Pharmacol, 2016, 173(3):459-70

PubMed: 26492939 ( click the link to review the publication )

Cancer Lett, 2016, 383(1):41-52

PubMed: 27693461 ( click the link to review the publication )

FASEB J, 2016, 30(1):201-13

PubMed: 26336913 ( click the link to review the publication )

ACS Infect Dis, 2016, 2(7):478-88

PubMed: 27626100 ( click the link to review the publication )

J Cell Sci, 2016, 129(6):1128-40

PubMed: 26823603 ( click the link to review the publication )

J Cell Sci, 2016, 129(13):2599-612

PubMed: 27206858 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2016, 311(2):L364-74

PubMed: 27261451 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2016, 311(2):L192-207

PubMed: 27288484 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2016, 311(3):L550-9

PubMed: 27402691 ( click the link to review the publication )

J Cyst Fibros, 2016, 15(4):425-35

PubMed: 26971626 ( click the link to review the publication )

J Cyst Fibros, 2016, 15(5):568-78

PubMed: 27160424 ( click the link to review the publication )

Respir Res, 2016, 17:8

PubMed: 26800689 ( click the link to review the publication )

PLoS One, 2016, 11(10):e0163615

PubMed: 27732613 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155882

PubMed: 27214033 ( click the link to review the publication )

J Bioenerg Biomembr, 2016, 48(3):197-210

PubMed: 27146408 ( click the link to review the publication )
JCI Insight, 2016,

PubMed: 27660821 ( click the link to review the publication )

J Chromatogr B Analyt Technol Biomed Life Sci, 2016, 1038:57-62

PubMed: 27792891 ( click the link to review the publication )

J Cell Sci, 2016, 129(6):1128-40

PubMed: 26823603 ( click the link to review the publication )

J Cell Sci, 2016, 129(13):2599-612

PubMed: 27206858 ( click the link to review the publication )

Nat Protoc, 2015, 10(3):363-81

PubMed: 25654755 ( click the link to review the publication )

Elife, 2015, 4e10365

PubMed: 26701908 ( click the link to review the publication )

Cell Mol Life Sci, 2015, 72(7):1363-75

PubMed: 25274064 ( click the link to review the publication )

Cell Mol Life Sci, 2015, 72(7):1363-75

PubMed: ( click the link to review the publication )

Stem Cell Reports, 2015, 4(4):569-77

PubMed: 25772471 ( click the link to review the publication )

Sci Signal, 2015, 8(377):ra48

PubMed: 25990958 ( click the link to review the publication )

Biochim Biophys Acta, 2015, 1853(5):892-903

PubMed: 25661196 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2015, 309(7):L687-99

PubMed: 26209275 ( click the link to review the publication )

J Cyst Fibros, 2015, 14(2):178-81

PubMed: 25467948 ( click the link to review the publication )

Cell Calcium, 2015, 57(1):38-48

PubMed: ( click the link to review the publication )

Cell Calcium, 2015, 57(1):38-48

PubMed: 25477137 ( click the link to review the publication )

Proteomics, 2015, 15(2-3):447-61

PubMed: 25330774 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123131

PubMed: 25879443 ( click the link to review the publication )

J Biomol Screen, 2015, 20(10):1204-17

PubMed: 26385858 ( click the link to review the publication )

J Vis Exp, 2015, (97)

PubMed: 25867140 ( click the link to review the publication )

Cell Calcium, 2015, 57(1):38-48

PubMed: 25477137 ( click the link to review the publication )

Sci Signal, 2015, 8(377):ra48

PubMed: 25990958 ( click the link to review the publication )

Sci Rep, 2015, 5:9038

PubMed: 25762484 ( click the link to review the publication )

F1000Res, 2015, 4:218

PubMed: 26594334 ( click the link to review the publication )

Pharmacol Res Perspect, 2015, 3(4):e00152

PubMed: 26171232 ( click the link to review the publication )
Sci Transl Med, 2014, 6(246):246ra96

PubMed: 25101886 ( click the link to review the publication )

Sci Transl Med, 2014, 6(246):246ra97

PubMed: 25101887 ( click the link to review the publication )

Br J Pharmacol, 2014, 171(19):4490-503

PubMed: 24902474 ( click the link to review the publication )

Biochem Pharmacol, 2014, 88(1):46-57

PubMed: 24412276 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2014, 307(1):L48-61

PubMed: 24816489 ( click the link to review the publication )

J Biol Chem, 2014, 289(52):35953-68

PubMed: 25384981 ( click the link to review the publication )

PLoS One, 2014, 9(9):e106842

PubMed: 25268501 ( click the link to review the publication )

Eur Biophys J, 2014, 43(6-7):341-6

PubMed: 24771136 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2014, 307(1):L48-61

PubMed: 24816489 ( click the link to review the publication )

Nat Chem Biol, 2013, 9(7):444-54

PubMed: 23666117 ( click the link to review the publication )

FASEB J, 2013, 28(2):791-801

PubMed: 24200884 ( click the link to review the publication )

Biochem Pharmacol, 2013, 86(5):612-9

PubMed: 23835419 ( click the link to review the publication )

Mol Pharmacol, 2013, 84(3):384-92

PubMed: 23788656 ( click the link to review the publication )

Am J Respir Cell Mol Biol, 2013, 49(3):445-52

PubMed: 23600628 ( click the link to review the publication )

PLoS One, 2013, 8(2):e57062

PubMed: 23460825 ( click the link to review the publication )

PLoS One, 2013, 8(5):e63167

PubMed: 23671668 ( click the link to review the publication )

Chem Biol, 2013, 20(7):943-55

PubMed: 23890012 ( click the link to review the publication )

Autophagy, 2012, 8(11):1657-72

PubMed: 22874563 ( click the link to review the publication )

Biochem Pharmacol, 2012, 83(3):345-54

PubMed: 22138447 ( click the link to review the publication )

J Biol Chem, 2012, 287(52):43630-8

PubMed: 23115232 ( click the link to review the publication )

产品安全说明书

CFTR抑制剂选择性比较

生物活性

产品描述

Lumacaftor (VX-809, VRT 826809)通过促进突变型CFTR(F508del-CFTR)的成熟，从而纠正囊性纤维症中常见的CFTR突变，在fisher大鼠甲状腺细胞中EC50为0.1 μM。Phase 3。

特性

在纠正CFTR缺陷方面，VX-809比之前报道的药物特异性更强，且更有效。

靶点

F508del-CFTR ^[1]
(Fisher rat thyroid cells)

0.1 μM(EC50)

体外研究

VX-809在雌激素受体（ER）水平上起作用的行为，使一部分F508del-CFTR采取正确折叠的方式，退出ER，转移到细胞表面，正常起作用。VX-809作用于表达 F508del-CFTR的Fischer 大鼠甲状腺 (FRT)细胞, VX-809显著提高F508del-CFTR突变，提高7.1 倍，EC50为0.1 μM, 且增强F508del-CFTR调节的氯离子运输，提高5 倍， EC50 为0.5 μM, 而VRT-768作用时具有更高的EC50 值，EC50分别为7.9 μM 和 16 μM。VX-809 (3 μM)作用于表达F508del-CFTR的HEK-293细胞,提高ER中的F508del-CFTR，提高6倍。VX-809作用于携带F508del-CFTR突变的原代人支气管上皮 (HBE)细胞，提高CFTR成熟度，且增强氯离子分泌，EC50分别为350 nM和81 nM,比Corr-4a和VRT-325更有效。VX-809修正的F508del-CFTR具有单通道开发概率，为0.39，与正常CFTR 类似，正常CFTR为0.40。与VX-770不同, VX-809不是CFTR增强剂，急剧加入VX-809不会对F508del-CFTR 功能造成影响。与VRT-325和Corr-4a相反, VX-809 不会促进正常或突变形式hERG 或P-gp的进程,及其他疾病引起错误定位的蛋白质，包括α1-抗胰蛋白酶Z突变 (E342K-α1-AT)或N370S-β-葡萄糖苷酶, 说明VX-809特异性作用于CFTR。

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
CFBE41o	NVvSVIIyS2:{cnXjeI9zKGG\|c3H5		NUj4bJB[OjRiaILz	MYrDc5Jz\WO2b4KgZYN1cX[rdImgZZQhS0[WUjDGOVA5NWSnbDDteZRidnRiKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gbJVu[W5iQ1\CSVQydyClZXzsd{Bp[XKkb4LpcochUFNvWV\QJJBz\WmwY4XiZZRm\CCob4KgNlQhcHK\|IH\vcIxwf2WmIHL5JIZwenOtb3zpck9o\W6rc4TlbY4he3SrbYXsZZRqd25iZn;yJFMxKG2rboOgZpkh\my3b4Lld4NmdmOnIHHzd4F6NCCHQ{WwJF0hOi53N{C0JO69VS5?	M2r4NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MkeyO\|Q6Lz5{OUK3Nlc1QTxxYU6=
FRT	Mlr4R49zemWldH;yJIF{e2G7		NH[0RWEzPSCvaX7z	NXzLW4lbS2:{cnXjeI9zKGGldHn2bZR6KGG2IHj1cYFvKEOIVGKgSlUxQCCmZXzleIlwdiCvdYThcpQh\XiycnXzd4VlKGmwIF\SWEBk\WyuczDpcoN2[mG2ZXSg[o9zKDJ3IH3pcpMhf2m2aDDmc5J{c2:uaX6gZpkhYU[SLXLhd4VlKG[udX;y[ZNk\W6lZTDhcoFtgXOrczDy[YxifGm4ZTD0c{Bkd262cn;sMEBGSzVyIE2gNk43KM7:TT6=	NIPYdlY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW2NVAxOyd-Mk[1OlExODN:L3G+
TC32	NUTDZ2JPeUiWUzDhd5NigQ>?			MVLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhXEN\|MjDj[Yxtew>?	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
U-2 OS	M2rXe5FJXFNiYYPzZZk>			MlL4dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFVvMjDPV{Bk\Wyucx?=	NFH0eo89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
A673	MorMdWhVWyCjc4PhfS=>			MVjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSTZ5MzDj[Yxtew>?	NWrsd3NORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
DAOY	NXzRfW9OeUiWUzDhd5NigQ>?			M4TkXJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCGQV;ZJINmdGy\|	NXu1bWZPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Saos-2	MXnxTHRUKGG\|c3H5			MmXUdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOjb4OtNkBk\Wyucx?=	NYn5W2F2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-37	NVPlVHc3eUiWUzDhd5NigQ>?			M{OxfJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2zO{Bk\Wyucx?=	NGCw[HY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
RD	M{faeJFJXFNiYYPzZZk>			M4fpWpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCURDDj[Yxtew>?	Mn63QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-SH	MlvZdWhVWyCjc4PhfS=>			MVLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3TTEBk\Wyucx?=	NEPyN\|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
BT-12	MmjOdWhVWyCjc4PhfS=>			MnvEdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUGyJINmdGy\|	M33UclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R)	NF2wSGlyUFSVIHHzd4F6			M3TlR5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCPRzC2N{ApPi2WRzDSLUBk\Wyucx?=	NFzOUIc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB1643	M{PQUJFJXFNiYYPzZZk>			M{fzfpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQkG2OFMh[2WubIO=	NILFcnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
BT-12	MYPxTHRUKGG\|c3H5			M3LMUpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGJVNTF{IHPlcIx{	M3vtTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
OHS-50	M4PJWpFJXFNiYYPzZZk>			M4LnWpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCRSGOtOVAh[2WubIO=	MkPwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
fibroblast cells	MlrXdWhVWyCjc4PhfS=>			M2jyVJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiClb370do9tKEiqIIfpcIQhfHmyZTDmbYJzd2KuYYP0JINmdGy\|	NV7oem05RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh41	MXXxTHRUKGG\|c3H5			M4nlfJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaESxJINmdGy\|	MmT2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh30	MXfxTHRUKGG\|c3H5			MWLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDSbFMxKGOnbHzz	NIHmRXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
U-2 OS	NHK3THdyUFSVIHHzd4F6			M{\PZpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHUuOiCRUzDj[Yxtew>?	M1TtfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41	MkCzdWhVWyCjc4PhfS=>			NGjSN2VyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBTcDRzIHPlcIx{	Mo\mQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
RD	NHvjWXNyUFSVIHHzd4F6			MlHBdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVmQh[2WubIO=	M1TyN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SJ-GBM2	NGW3bmZyUFSVIHHzd4F6			NXT2OWo4eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPKMWdDVTJiY3XscJM>	MmjOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC	MU\xTHRUKGG\|c3H5			M4ezcJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMW1EKGOnbHzz	MlKzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
NB-EBc1	MXvxTHRUKGG\|c3H5			MWHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJvRVLjNUBk\Wyucx?=	MnraQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
LAN-5	NX3R[YF{eUiWUzDhd5NigQ>?			MnrGdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEyDTj21JINmdGy\|	NH7LWlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh18	NWrrU\|JLeUiWUzDhd5NigQ>?			NHT1RZlyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUnixPEBk\Wyucx?=	M1O2NFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
CFBE41o	NH6zV\|FEd3K{ZXP0c5Ih[XO\|YYm=	M33OSFEhfU1?	MYOyOEBpenN?	NFvKOWNEd3K{ZXP0c5Ih[WO2aY\peJkh[XRiQ1\UVkBHPTB6LXTlcEBufXSjboSgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO\|ZXSgbY4hcHWvYX6gR2ZDTTRzbzDj[YxteyCqYYLic5JqdmdiSGOtXWZRKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJI1ifHW{ZXSgdJJwfGWrbjDs[ZZmdHNiYYSgZ4VtdCC\|dYLmZYNmKGG2IEGgeW0h[W[2ZYKgNlQhcHK\|IHL5JIVt\WO2cn;wbI9z\XSrYzDtc4JqdGm2eTDhd5NigQ>?	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTJ5Mke0PUc,Ojl{N{K3OFk9N2F-
HBE	MnjpR49zemWldH;yJIF{e2G7			NUPK[oM3S2:{cnXjeI9zKGGldHn2bZR6KGG2IFPGWHIhTjVyOHTlcE9HPTB6ZHXsJI12fGGwdDDpckBxemmvYYL5JGhDTSClZXzsd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDjbIxwemmmZTDpc44h[3W{cnXueEBi[3Kxc4OgZZBq[2GuIH3lcYJz[W6nIH3lZZN2emWmIEG4JJRwKDJ2IHjyd{Bxd3O2IHPvcZBwfW6mIITy[YF1dWWwdDDvckBj[XOxbHH0[ZJidCC\|aXTlJI9nKGOnbHzzJIlvKHC{ZYPlcoNmKG:oIHPoZY5v\WxicH;0[Y51cWG2b4KgS2xRTzF6	NIDK[GY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUK1NVk{Oid-MkmyOVE6OzJ:L3G+
CFBE41o	M1r6PGNwenKnY4TvdkBie3OjeR?=			MWDDc5Jz\WO2b4KgZYN1cX[rdImgZZQhS0[WUjDGOVA5\GWuIH31eIFvfCBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDoeY1idiCFRlLFOFFwKGOnbHzzJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIH\1cIx6KGeueXPvd5lt[XSnZDDwdo91\WmwIHL5JJdme3Sncn6gZoxwfCCjbnHsfZNqew>?	NHPKZ5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC0NVU4Pyd-Mk[wOFE2Pzd:L3G+
CFBE41o	M4HqemNwenKnY4TvdkBie3OjeR?=	MUWxJJVO	NWr3c4R{OjRiaILz	NFe1XmhEd3K{ZXP0c5Ih[WO2aY\peJkh[XRiQ1\UVkBHPTB6ZHXsJI12fGGwdDCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBpfW2jbjDDSmJGPDGxIHPlcIx{KGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJJNqgmVib3[gZ2FOWC2mZYDlcoRmdnRiY4XydoVvfCCjdDCxJJVOKGGodHXyJFI1KGi{czDt[YF{fXKnZDDheEAsOTByIH3WJIJ6KHeqb3zlJINmdGxicHH0Z4gh[2yjbYCgZZN{[Xl?	NVP5NJhpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wOFE2PzdpPkK2NFQyPTd5PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Immunofluorescence	CFTR / USP13; PubMed: 30618756 Front Pharmacol Confocal microscope images taken from CFBE41o- cells stained with antibodies against CFTR and USP13. Cells were treated with VX-809 (1 μM) or vehicle. Arrows indicate examples of cells with peripheral co-localization of F508del-CFTR and USP13. Arrowheads show peripheral regions with USP13 alone. Insets depict magnified cell areas of cell periphery with colocalization of USP13 and F508del-CFTR. Cell surface kAE1 / kAE1; PubMed: 23460825 PLoS One MDCK cells expressing WT or kAE1 mutant were either kept in control conditions or treated with 3 µM of the molecular chaperone VX-809 for 24 hours prior to fixation. We then performed a two-step immunostaining as follows: cells were blocked and stained with a mouse anti-HA antibody followed by staining with an Alexa 488 coupled secondary antibody. Cells were then permeabilized and after blocking, stained again with a mouse anti-HA antibody followed by a Cy3 coupled secondary antibody. The samples were examined with a WaveFx spinning disk using a 60×oil immersion objective. The size bar corresponds to 10 µm	30618756 23460825

激酶实验：^[1]	- 合并 F508del-CFTR成熟度: 用浓度不断增高的VX-809处理稳定表达F508del-CFTR的Fischer大鼠甲状腺(FRT)细胞48小时。温育后，细胞收集在冰冻D-PBS溶液中 (没有钙和镁)，然后按1,000 × g 转速在4^oC下离心。细胞颗粒溶解1% Nonidet P-40, 0.5%去氧胆酸钠，200 mM NaCl, 10 mM Tris, pH 7.8, 及 1 mM EDTA和蛋白酶抑制剂混合物中(1:250)，然后在冰上放置30分钟。裂解物在10,000×g转速4^oC下旋转10分钟，将细胞核和不溶性物质制成颗粒状。12 μg 全部蛋白在Laemmli buffer 中与5% β-巯基乙醇在37^oC加热5分钟，然后上样到3% 到8% Tris-乙酸凝胶上。凝胶转移到硝化纤维素中，使用单克隆CFTR抗体或 GAPDH多克隆抗体进行 Western blotting。通过增强发光而进行印迹。通过扫描片的 NIH ImageJ 分析而而测量C带和GAPDH的相对量。
细胞实验：^[1]	- 合并 Cell lines: FRT(CFTR 或 F508del-CFTR), HEK-293 (CFTT 或 F508del-CFTR), 和HBE Concentrations: 溶于DMSO, 终浓度为~0.1 mM Incubation Time: 24 或 48 小时 Method: 使用浓度不断增高的VX-809处理细胞24或48小时。使用Ussing chamber技术记录 CFTR介导氯离子运输中的跨膜电流 (IT)结果。通过使用离体的内面外向式膜片钳测量CFTR单通道活性。使用单克隆CFTR 抗体及免疫印迹技术测量表达CFTR或F508del-CFTR的FRT, HEK-293, 或 HBE细胞中CFTR成熟度。 (Only for Reference)

参考文献

[1] Van Goor F, et al. Proc Natl Acad Sci U S A, 2011, 108(46), 18843-18848.

溶解度 (25°C)

体外	DMSO	90 mg/mL (198.93 mM)
	Water	Insoluble
	Ethanol	'6 mg/mL
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 30% PEG400+0.5% Tween80+5% propylene glycol	30 mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Lumacaftor (VX-809) SDF

分子量	452.41
化学式	C₂₄H₁₈F₂N₂O₅
CAS号	936727-05-8
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	VRT 826809

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

g

每只动物给药体积

ul

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-05-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03512119	Completed	Drug: Lumacaftor-Ivacaftor treatment	Cystic Fibrosis Homozygous for Phe 508 Del CFTR\|Glucose Intolerance or Newly Diagnosis Diabetes	University Hospital Strasbourg France	February 11 2016	--
NCT02514473	Completed	Drug: VX-809\|Drug: Placebo\|Drug: VX-770	Cystic Fibrosis	Vertex Pharmaceuticals Incorporated	July 2015	Phase 3
NCT01899105	Completed	Drug: lumacaftor\|Drug: ivacaftor	Cystic Fibrosis	Vertex Pharmaceuticals Incorporated	July 2013	Phase 1
NCT01897233	Completed	Drug: Lumacaftor\|Drug: Ivacaftor	Cystic Fibrosis	Vertex Pharmaceuticals Incorporated	July 2013	Phase 3

研究领域

产品类型

定制您的化合物库

Lumacaftor (VX-809)

客户使用Selleck生产的Lumacaftor (VX-809)发表文献164篇：

产品安全说明书

CFTR抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Lumacaftor (VX-809) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-05-17)

技术支持

CFTR Signaling Pathway Map

相关CFTR产品